OPKO Health, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
OPKO Health, Inc. (OPK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.64% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-02-26
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.64%, a 5.51% increase from fiscal 2024.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.45%, a 4.43% decline from fiscal 2023.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.61%, a 111.11% increase from fiscal 2022.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.71%, a 402.94% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month as first filed |
|---|---|---|
| 2025-12-31 | 3.64% 10-K · filed 2026-02-26 | |
| 2024-12-31 | 3.45% 10-K · filed 2026-02-26 | |
| 2023-12-31 | 3.61% 10-K · filed 2026-02-26 | |
| 2022-12-31 | 1.71% 10-K · filed 2025-03-03 | |
| 2021-12-31 | 0.34% 10-K · filed 2024-03-01 | |
| 2020-12-31 | 0.16% 10-K · filed 2023-02-27 | |
| 2019-12-31 | 1.35% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 2.32% 10-K · filed 2021-02-18 | |
| 2017-12-31 | 1.32% 10-K · filed 2020-03-02 | |
| 2016-12-31 | 0.71% 10-K · filed 2019-03-01 | |
| 2015-12-31 | 0.26% 8-K · filed 2019-01-29 | |
| 2014-12-31 | 0.10% 10-K · filed 2017-03-01 | |
| 2013-12-31 | 0.15% 10-K · filed 2016-02-29 | |
| 2012-12-31 | 0.09% 10-K · filed 2015-02-27 | 0.34% 10-K · filed 2013-03-18 |
| 2011-12-31 | 1.30% 10-K · filed 2014-03-03 | 0.09% 10-K · filed 2013-03-18 |
| 2010-12-31 | 1.30% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |